Cytokinetics to Hold Annual Meeting of Stockholders
May 07 2020 - 4:00PM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its
Annual Meeting of Stockholders will be held on Wednesday, May 13,
2020 at 10:30 AM Pacific Time at the Company’s headquarters, 280
East Grand Avenue, South San Francisco, CA. Immediately after the
conclusion of the Annual Meeting of Stockholders, Robert I. Blum,
President and Chief Executive Officer, is scheduled to present an
overview of Cytokinetics’ performance.
Due to the COVID-19 pandemic, Cytokinetics will
be taking certain precautionary measures to ensure the health and
safety of those in attendance. Attendees will be required to wear a
face mask, comply with social distancing guidelines and pass a
touchless, infrared temperature check prior to entering
Cytokinetics’ facilities. Anyone exhibiting fever or flu-like
symptoms will not be allowed entry to the building.
Stockholders of record at the close of business
on March 23, 2020 are entitled to vote at Cytokinetics’ Annual
Meeting of Stockholders or to submit questions to management.
Stockholders wishing to vote must attend the meeting in person or
submit a valid proxy card by mail, telephone or internet by 11:59
PM Eastern Time on May 12, 2020, in accordance with instructions
contained in our Proxy Statement and our Notice of Internet
Availability of Proxy Materials for the 2020 Annual Meeting of
Stockholders.
Interested parties may access the live webcast
of the Annual Meeting of Stockholders and the subsequent
presentation by visiting the Investors & Media section of
Cytokinetics’ website at www.cytokinetics.com. The live audio of
the conference call can also be accessed by telephone by dialing
either (866) 999-CYTK (2985) (United States and Canada) or (706)
679-3078 (international) and typing in the passcode
9156988.
An archived replay of the webcast will be
available via Cytokinetics’ website until May 20, 2020. The replay
will also be available via telephone by dialing (855) 859-2056
(United States and Canada) or (404) 537-3406 (international) and
typing in the passcode 9156988 from May 13, 2020 at 1:30 PM Pacific
Time until May 20, 2020.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators and next-in-class muscle
inhibitors as potential treatments for debilitating diseases in
which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to impact muscle function and
contractility. Cytokinetics is collaborating with Amgen Inc.
(Amgen) to develop omecamtiv mecarbil, a novel cardiac muscle
activator. Omecamtiv mecarbil is the subject of an international
clinical trials program in patients with heart failure including
GALACTIC-HF and METEORIC-HF. Amgen holds an exclusive worldwide
license to develop and commercialize omecamtiv mecarbil with a
sublicense held by Servier for commercialization
in Europe and certain other countries. Cytokinetics is
developing reldesemtiv, a fast skeletal muscle troponin activator
(FSTA) for the potential treatment of ALS and other neuromuscular
indications following conduct of FORTITUDE-ALS and other Phase 2
clinical trials. The company is considering potential advancement
of reldesemtiv to Phase 3 pending ongoing regulatory interactions.
Cytokinetics is collaborating with Astellas Pharma Inc. (Astellas)
to research, develop and commercialize other novel mechanism
skeletal sarcomere activators (not including FSTAs). Licenses held
by Amgen and Astellas are subject to specified co-development and
co-commercialization rights of Cytokinetics. Cytokinetics is also
developing CK-274, a novel cardiac myosin inhibitor that company
scientists discovered independent of its collaborations, for the
potential treatment of hypertrophic cardiomyopathies (HCM).
Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of
CK-274 in patients with obstructive HCM. Cytokinetics continues its
over 20-year history of pioneering innovation in muscle biology and
related pharmacology focused to diseases of muscle dysfunction and
conditions of muscle weakness.
For additional information
about Cytokinetics, visit www.cytokinetics.com and follow
us on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements and claims
the protection of the Act's Safe Harbor for
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating to Cytokinetics' and
its partners' research and development activities of Cytokinetics’
product candidates. Such statements are based on management's
current expectations, but actual results may differ materially due
to various risks and uncertainties, including, but not limited to
the risks related to Cytokinetics' business outlined in
Cytokinetics' filings with the Securities and Exchange
Commission. Forward-looking statements are not guarantees of future
performance, and Cytokinetics' actual results of operations,
financial condition and liquidity, and the development of the
industry in which it operates, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that Cytokinetics makes in this press
release speak only as of the date of this press release.
Cytokinetics assumes no obligation to update its forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
Contact:CytokineticsDiane WeiserSenior Vice
President, Corporate Communications, Investor Relations(415)
290-7757
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2023 to Sep 2024